ObjectivesThe purpose of this study was to determine whether the speed of response to clopidogrel loading predicts the final degree of response.BackgroundFast inhibition of platelet aggregation is important in the setting of acute coronary syndromes and percutaneous coronary intervention, but its association with the final degree of inhibition is not well established.MethodsWe performed a post hoc analysis of the ALBION study; early kinetic profiles of adenosine diphosphate 20 μmol/l maximal platelet aggregation (MPA) and ΔMPA (with baseline sample as reference) were studied at 8 time points within the 24 h after clopidogrel loading (300, 600, or 900 mg) in non–ST-segment elevation acute coronary syndrome patients. Low response was defined ...
Body weight is a predictor of clopidogrel response. However, no prospective studies have compared ph...
ObjectivesWe sought to determine whether nonresponsiveness to clopidogrel as revealed by high in vit...
Prasugrel is more effective than clopidogrel in reducing platelet aggregation in acute coronary synd...
ObjectivesTo determine if the speed of response to clopidogrel loading predicts the final degree of ...
ObjectivesThe purpose of this study was to determine whether the speed of response to clopidogrel lo...
BackgroundA heterogeneous platelet reactivity response to clopidogrel exists, and the clinical or bi...
SummaryBackgroundLarge interindividual variability exists in clopidogrel response. Clopidogrel low r...
ObjectivesThe aim of this study was to evaluate the correlation of point-of-care measurement of plat...
ObjectivesWe determined the effect of clopidogrel dosing on the incidence of nonresponsiveness (NR) ...
Background: Clopidogrel, especially when combined with aspirin, reduces the rate of ischaemic events...
ObjectivesThe aim of this prospective trial was to assess whether platelet reactivity to clopidogrel...
ObjectivesWe investigated whether maintenance therapy with clopidogrel 150 mg/day produces greater p...
ObjectivesWe sought to describe the responses of patients to clopidogrel using ex vivo measures of p...
Background: Clopidogrel is a widely used antithrombotic agent that inhibits the platelet P2Y12 adeno...
Objective: Clopidogrel therapy is the standard of care in patients with acute coronary syndrome (ACS...
Body weight is a predictor of clopidogrel response. However, no prospective studies have compared ph...
ObjectivesWe sought to determine whether nonresponsiveness to clopidogrel as revealed by high in vit...
Prasugrel is more effective than clopidogrel in reducing platelet aggregation in acute coronary synd...
ObjectivesTo determine if the speed of response to clopidogrel loading predicts the final degree of ...
ObjectivesThe purpose of this study was to determine whether the speed of response to clopidogrel lo...
BackgroundA heterogeneous platelet reactivity response to clopidogrel exists, and the clinical or bi...
SummaryBackgroundLarge interindividual variability exists in clopidogrel response. Clopidogrel low r...
ObjectivesThe aim of this study was to evaluate the correlation of point-of-care measurement of plat...
ObjectivesWe determined the effect of clopidogrel dosing on the incidence of nonresponsiveness (NR) ...
Background: Clopidogrel, especially when combined with aspirin, reduces the rate of ischaemic events...
ObjectivesThe aim of this prospective trial was to assess whether platelet reactivity to clopidogrel...
ObjectivesWe investigated whether maintenance therapy with clopidogrel 150 mg/day produces greater p...
ObjectivesWe sought to describe the responses of patients to clopidogrel using ex vivo measures of p...
Background: Clopidogrel is a widely used antithrombotic agent that inhibits the platelet P2Y12 adeno...
Objective: Clopidogrel therapy is the standard of care in patients with acute coronary syndrome (ACS...
Body weight is a predictor of clopidogrel response. However, no prospective studies have compared ph...
ObjectivesWe sought to determine whether nonresponsiveness to clopidogrel as revealed by high in vit...
Prasugrel is more effective than clopidogrel in reducing platelet aggregation in acute coronary synd...